Suppliers / Jiangsu Grand Xianle Pharmaceutical

Jiangsu Grand Xianle Pharmaceutical

China Updated 9 July 2026

Jiangsu Grand Xianle Pharmaceutical is an API manufacturer based in China. It holds one active US drug master file and 5 valid CEPs across a filed portfolio of 6 molecules. Its GMP standing is certified by EMA.

1
active US DMFs
5
valid CEPs
2
registered plants
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
EU GMP
1 of 1 confirmed
Sources: EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
Yancheng, China Not on file
Yancheng City, China Not on file

What they file, and where

Molecule Regulators Docs
Betamethasone EDQM 1
Clobetasol Propionate EDQM 1
Cyproterone EDQM 1
Medroxyprogesterone Acetate EDQM 1
Megestrol Acetate US FDA 1
Prednisolone EDQM 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA None 2

Comparing suppliers?

Choose your molecules and target markets. Jiangsu Grand Xianle Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates